Review: The role of insulin resistance in nonalcoholic fatty liver disease

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 12, 2006, Pages 4753-4761

  Utzschneider, Kristina M ^a,b   Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; AMIODARONE; ESTROGEN; FATTY ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE; TAMOXIFEN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ADIPOSE TISSUE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FAT INTAKE; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID STORAGE; LIPOGENESIS; LIVER BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ULTRASOUND; WEIGHT REDUCTION;

EID: 33845490856     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0587     Document Type: Review

References (118)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ 1999 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419
2. Teli MR, James OF, Burt AD, Bennett MK, Day CP 1995 The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22:1714-1719
3. Lee RG 1989 Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20:594-598
4. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J 2002 NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379
5. Chalasani N, Deeg MA, Persohn S, Crabb DW 2003 Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:1849-1855
6. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G 2003 Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:909-916
7. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G 2001 Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 36:1117-1124
8. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA 2001 Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96:2957-2961
9. Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Jarvinen H 2002 Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 10:859-867
10. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN 2001 Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192
11. Ground KE 1982 Liver pathology in aircrew. Aviat Space Environ Med 53:14-18
12. Hilden M, Christoffersen P, Juhl E, Dalgaard JB 1977 Liver histology in a "normal" population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12:593-597
13. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C 2000 Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-117
14. Dixon JB, Bhathal PS, O'Brien PE 2001 Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100
15. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R 2000 Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33:716-724
16. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa 2004 Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19:854-858
17. Akbar DH, Kawther AH 2003 Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 26:3351-3352
18. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G 2005 Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546
19. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA 2002 High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889-1895
20. Wanless IR, Lentz JS 1990 Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-1110
21. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K 2005 The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722-728
22. Fan JG, Zhu J, Li XJ, Chen L, Lu YS, Li L, Dai F, Li F, Chen SY 2005 Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 20:1825-1832
23. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395
24. Flegal KM, Carroll MD, Ogden CL, Johnson CL 2002 Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727
25. Moran JR, Ghishan FK, Halter SA, Greene HL 1983 Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 78:374-377
26. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE 1995 Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 127:700-704
27. Chitturi S, Farrell GC 2001 Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21:27-41
28. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N 2001 Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850
29. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M 2005 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634-642
30. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H 2002 Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028
31. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE 2002 The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005-1015
32. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L 2000 Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 23:465-471
33. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA 2002 Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135-E1143
34. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY 2003 Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care 26:650-655
35. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, Kahn SE 2003 The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 52:172-179
36. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE 2003 Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care 26:1413-1420
37. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE 2004 Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087-2094
38. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC 2003 Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906-E916
39. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R 2003 Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 284:E1065-E1071
40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ 2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1351
41. Jensen MD, Johnson CM 1996 Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metabolism 45:662-666
42. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD 2001 Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 280:E1000-E1006
43. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
44. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469
45. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295
46. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J 2004 Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40:46-54
47. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G 2005 Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498-3504
48. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA 2004 Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789
49. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ 2003 The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100
50. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G 2003 Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88:5321-5326
51. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
52. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G 2001 Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751
53. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W 2001 Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154-1159
54. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D 2003 Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799-1804
55. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL 2003 Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625-633
56. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA 2003 Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 27:88-94
57. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, Cayon A, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F 2001 Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 11:254-257
58. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ 2003 Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413-419
59. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F 2001 Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-1163
60. Kim SP, Ellmerer M, Van Citters GW, Bergman RN 2003 Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52:2453-2460
61. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI 2004 Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353
62. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, Yki-Jarvinen H 2005 Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90:2804-2809
63. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J 1996 Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest 97:2081-2091
64. Day C, Saksena S 2002 Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 17(Suppl 3):S377-S384
65. Luyckx FH, Lefebvre PJ, Scheen AJ 2000 Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 26:98-106
66. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A 2003 Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 284:E863-E873
67. Tamura S, Shimomura I 2005 Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115:1139-1142
68. Shimano H, Horton JD,Shimomura I, Hammer RE, Brown MS, Goldstein JL 1997 Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854
69. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N 2002 Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277:19353-19357
70. Browning JD, Horton JD 2004 Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152
71. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M 2004 Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432:1027-1032
72. Biddinger SB, Kahn CR 2006 From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 68:123-158
73. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR 2003 Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38:1008-1017
74. Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T, Ishii H 2002 A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis. Hepatology 36:A406
75. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS 2004 A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2:1107-1115
76. Promrat K, Lutchman G, Uwaifo G, Freedman R, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang T, Yanovski J, Kleiner D, Hoofnagle J 2004 A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196
77. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI 2005 Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-608
78. Neuschwander-Tetri BA, Caldwell SH 2003 Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219
79. Park HS, Kim MW, Shin ES 1995 Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 10:414-421
80. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K 1997 Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107
81. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P 2005 Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43:1060-1066
82. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS 2005 One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100:1072-1081
83. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H 2003 Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52:701-707
84. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R 2005 Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196
85. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ 1998 Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22:222-226
86. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
87. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE 2001 Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
88. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM 2000 Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998-1003
89. Nair S, Diehl AM, Wiseman M, Farr Jr GH, Perrillo RP 2004 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20:23-28
90. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N 2001 Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894
91. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G 2005 A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082-1090
92. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K 2004 Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537-544
93. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H 2004 Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176
94. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
95. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791
96. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, Nuutila P 2003 Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290
97. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF 2001 Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871
98. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF 2002 The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
99. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, Fanghanel-Salmon G, Gallegos-Martinez J, Gomez-Diaz RA, Salinas-Orozco S, Chavira-Lopez IJ, Sanchez-Reyes L, Torres-Acosta EM, Tamez R, Lopez A, Guillen LE, Cesarman G 2002 Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism 51:44-51
100. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM 2002 The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974
101. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR 2003 Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667-674
102. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM 2002 Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380
103. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162
104. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ 2001 Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 59:765-773
105. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Plutzky J 2002 PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703-710
106. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W 2003 Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283-288
107. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC 2003 Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26:172-178
108. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, McVeety JC, Horwitz RI 2003 Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 34:1431-1436
109. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT 2004 Effects of rosiglitazone on endothelial function, C-reactive protein,andcomponents of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93:362-365
110. Acosta R, Molina E, O'Brien C, Cobo M, Amaro R, Neff G, Schiff E 2001 The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 120:A546
111. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, Tzioufa V, Dimitrios K 2004 Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 23:131-134
112. Rallidis LS, Drakoulis CK, Parasi AS 2004 Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 174:193-196
113. Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S, Yoshida S 2003 Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol Rep 10:1473-1478
114. Basaranoglu M, Acbay O, Sonsuz A 1999 A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31:384
115. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH 2006 Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 40:S51-S60
116. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P 2004 Ursodeoxycholicacid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778
117. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH 2005 Roux-en-Y gastric bypass improves liver histology in patients with nonalcoholic fatty liver disease. Obes Res 13:1180-1186
118. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL 2001 A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519-525